Imbruvica Now Also Approved for Children with Chronic Graft-VersusHost Disease.
- Published in:
- Conquer, 2022, v. 8, n. 5, p. 50
- Publication type:
- Article
Works matching IS 2475823X AND DT 2022 AND VI 8 AND IP 5
Results: 25
1
2
Pemazyre Approved for Patients with FGFR1-Positive Myeloid/ Lymphoid Neoplasms.
- Published in:
- Conquer, 2022, v. 8, n. 5, p. 50
- Publication type:
- Article
3
Enhertu First Drug Approved for Advanced Lung Cancer and HER2 Gene Mutation.
- Published in:
- Conquer, 2022, v. 8, n. 5, p. 49
- Publication type:
- Article
4
Retevmo Approved for Advanced Solid Tumors and RET Fusion.
- Published in:
- Conquer, 2022, v. 8, n. 5, p. 48
- Publication type:
- Article
5
Vegzelma a New Biosimilar Approved for the Treatment of 6 Types of Solid Tumors.
- Published in:
- Conquer, 2022, v. 8, n. 5, p. 48
- Publication type:
- Article
6
Imfinzi Approved for Advanced or Metastatic Biliary Tract Cancer.
- Published in:
- Conquer, 2022, v. 8, n. 5, p. 47
- Publication type:
- Article
7
Lytgobi Newest Drug Approved for Patients with FGFR2-Positive Cholangiocarcinoma.
- Published in:
- Conquer, 2022, v. 8, n. 5, p. 47
- Publication type:
- Article
8
Nubeqa Approved for Men with Metastatic Hormone-Sensitive Prostate Cancer.
- Published in:
- Conquer, 2022, v. 8, n. 5, p. 31
- Publication type:
- Article
9
A Brief Guide to Triple-Negative Breast Cancer.
- Published in:
- Conquer, 2022, v. 8, n. 5, p. 40
- Publication type:
- Article
10
Defined by Cancer, or I Defy My Cancer?
- Published in:
- Conquer, 2022, v. 8, n. 5, p. 38
- By:
- Publication type:
- Article
11
Ten Years Cancer-Free.
- Published in:
- Conquer, 2022, v. 8, n. 5, p. 34
- By:
- Publication type:
- Article
12
Dealing with Chest Numbness After Mastectomy.
- Published in:
- Conquer, 2022, v. 8, n. 5, p. 32
- By:
- Publication type:
- Article
13
How Planning and Organization Helped in My Breast Cancer Journey.
- Published in:
- Conquer, 2022, v. 8, n. 5, p. 35
- By:
- Publication type:
- Article
14
I Found a Lump on My Left Breast Yesterday.
- Published in:
- Conquer, 2022, v. 8, n. 5, p. 29
- By:
- Publication type:
- Article
15
Ode to My Friend.
- Published in:
- Conquer, 2022, v. 8, n. 5, p. 28
- By:
- Publication type:
- Article
16
Navigating Patient Communications Through Cancer.
- Published in:
- Conquer, 2022, v. 8, n. 5, p. 25
- By:
- Publication type:
- Article
17
Addressing Disparities in the Care of Patients with TripleNegative Breast Cancer.
- Published in:
- Conquer, 2022, v. 8, n. 5, p. 22
- By:
- Publication type:
- Article
18
Enhertu First Drug Approved for Patients with HER2-Low Breast Cancer.
- Published in:
- Conquer, 2022, v. 8, n. 5, p. 11
- Publication type:
- Article
19
My Race to Be Cancer-Free.
- Published in:
- Conquer, 2022, v. 8, n. 5, p. 9
- By:
- Publication type:
- Article
20
Traditional versus Alternative Therapies: What Is the Difference?
- Published in:
- Conquer, 2022, v. 8, n. 5, p. 19
- By:
- Publication type:
- Article
21
Painting Helped Me Get Through Cancer Treatment.
- Published in:
- Conquer, 2022, v. 8, n. 5, p. 14
- By:
- Publication type:
- Article
22
Listening to Yourself: Lessons from My Triple-Negative Breast Cancer Diagnosis.
- Published in:
- Conquer, 2022, v. 8, n. 5, p. 16
- By:
- Publication type:
- Article
23
A Breast Cancer Diagnosis and Stumbling into Advocacy in Nigeria.
- Published in:
- Conquer, 2022, v. 8, n. 5, p. 12
- By:
- Publication type:
- Article
24
When Cancer Asked Me What I Was Made Of.
- Published in:
- Conquer, 2022, v. 8, n. 5, p. 6
- By:
- Publication type:
- Article
25
Better Patient Care, Better Outcome.
- Published in:
- Conquer, 2022, v. 8, n. 5, p. 5
- By:
- Publication type:
- Article